The latest price target for GeneDx Hldgs (NASDAQ:WGS) was reported by TD Cowen on January 7, 2025. The analyst firm set a price target for $118.00 expecting WGS to rise to within 12 months (a possible 69.83% upside). 18 analyst firms have reported ratings in the last year.

The latest analyst rating for GeneDx Hldgs (NASDAQ:WGS) was provided by TD Cowen, and GeneDx Hldgs maintained their buy rating.

There is no last upgrade for GeneDx Hldgs

There is no last downgrade for GeneDx Hldgs.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GeneDx Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GeneDx Hldgs was filed on January 7, 2025 so you should expect the next rating to be made available sometime around January 7, 2026.

While ratings are subjective and will change, the latest GeneDx Hldgs (WGS) rating was a maintained with a price target of $75.00 to $118.00. The current price GeneDx Hldgs (WGS) is trading at is $69.48, which is out of the analyst’s predicted range.